Results 111 to 120 of about 16,946 (180)

SEGUIMIENTO DEL CÁNCER DE OVARIO: ¿LAPAROSCOPIA O LAPAROTOMÍA?

Medicentro, 2011
Se revisaron 93 historias clínicas de pacientes con diagnóstico de cáncer de ovario, que fueron tratadas en el Hospital Universitario “Celestino Hernández Robau” de Villa Clara, desde 1998 al 2003, con el objetivo de demostrar el valor de la laparoscopia
María Emilia Fernández Aguilar, Elda Areli Manrique Rionda, Marlene Valdés Cancio, Elisa Marchena Pérez, María de los Milagros Castro Valencia, Pedro Vázquez González   +5 more
doaj  

Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents? [PDF]

Rev Bras Ginecol Obstet, 2017
Jammal MP, Lima CA, Murta EFC, Nomelini RS.   +3 more
europepmc   +1 more source

Cáncer de mama y ovario hereditario:consejo genético, seguimiento y reducción del riesgo [PDF]

Of the approximately 16.000 new cases of breast cancer annually diagnosed in Spain, between 5 and 10% are hereditary. A family history of breast cancer is the main criterion to suspect that we could be facing a case of hereditary breast cancer (HBC ...
Cueva, Juan, Graña, Begoña, Vega, Ana
core   +1 more source

Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer. [PDF]

Rev Col Bras Cir, 2022
Faria FH, Lage APD, Rodrigues AN, Wainstein AJA.   +3 more
europepmc   +1 more source

Psychological impact and intervention needs in genetic counseling for women with hereditary breast cancer risk [PDF]

Se exponen los aspectos psicológicos del Consejo Genético Oncológico en cáncer de mama (CGO). El CGO tiene como beneficio principal para los participantes obtener certidumbre, ser capaces de estimar el riesgo de desarrollar cáncer hereditario, adoptar ...
Cruzado, Juan A., Olivera, Helena, Pérez Segura, Pedro P.   +2 more
core   +1 more source

[PAPPS Expert Groups. Cancer prevention recommendations: Update 2022]. [PDF]

Aten Primaria, 2022
Marzo-Castillejo M, Bartolomé-Moreno C, Bellas-Beceiro B, Melús-Palazón E, Vela-Vallespín C.   +4 more
europepmc   +1 more source

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. [PDF]

Br J Cancer, 2023
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A, INOVATYON study group.   +41 more
europepmc   +1 more source

[2018-2024 Cancer Trends in Pathology of a Hospital in Eastern Mexico]. [PDF]

Rev Med Inst Mex Seguro Soc
González-Zago A, Fierro-Atondo FA, Ramírez-Juárez N, Pérez-Corro MÁ, Anaya-Ruiz M, Maycotte P.   +5 more
europepmc   +1 more source

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer. [PDF]

Future Oncol
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melou AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Nieuwenhuysen EV, DUO-E Investigators.   +29 more
europepmc   +1 more source

Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study "Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer": The International NOGGO, ENGOT, and GCIG Survey. [PDF]

Cancers (Basel)
Dimitrova D, Samartzis EP, Zocholl D, Barretina-Ginesta MP, Leitner K, Havelka P, Achimas-Cadariu P, Taskiran C, Mittelstadt S, Van Nieuwenhuysen E, Bauerschmitz G, Heinzelmann-Schwarz V, Madariaga A, Ringsdorf U, Zwimpfer T, Madroñal C, Enzinger HM, Al Rubaish S, Sehouli J, Woopen H.   +19 more
europepmc   +1 more source